About Cogent Biosciences, Inc.
https://www.cogentbio.comCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.
CEO
Andrew R. Robbins
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-11-09 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 129
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Guggenheim
Buy
Citigroup
Buy
Jefferies
Buy
Leerink Partners
Outperform
JP Morgan
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
FMR LLC
Shares:22.41M
Value:$846.81M
BLACKROCK, INC.
Shares:10.37M
Value:$391.86M
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Shares:9.05M
Value:$342.12M
Summary
Showing Top 3 of 218
About Cogent Biosciences, Inc.
https://www.cogentbio.comCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $83.36M ▲ | $-80.93M ▼ | 0% | $-0.71 ▼ | $-78.83M ▼ |
| Q2-2025 | $0 | $74.42M ▼ | $-73.53M ▼ | 0% | $-0.64 ▼ | $-72.06M ▲ |
| Q1-2025 | $0 | $74.93M ▲ | $-71.99M ▼ | 0% | $-0.52 ▲ | $-73.8M ▼ |
| Q4-2024 | $0 | $73.73M ▼ | $-67.93M ▲ | 0% | $-0.61 ▲ | $-72.63M ▲ |
| Q3-2024 | $0 | $75.41M | $-70.63M | 0% | $-0.64 | $-74.32M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $390.89M ▲ | $425.93M ▲ | $123.47M ▲ | $302.46M ▲ |
| Q2-2025 | $237.85M ▼ | $274.82M ▼ | $119.78M ▲ | $155.04M ▼ |
| Q1-2025 | $245.66M ▼ | $283.8M ▼ | $64.8M ▼ | $219M ▼ |
| Q4-2024 | $287.08M ▼ | $327.9M ▼ | $71.61M ▲ | $256.29M ▼ |
| Q3-2024 | $335.52M | $384.02M | $69.36M | $314.66M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-80.93M ▼ | $-64.29M ▼ | $-155.05M ▼ | $217.37M ▲ | $-2.3M ▼ | $-64.35M ▼ |
| Q2-2025 | $-73.53M ▼ | $-54.54M ▲ | $8.91M ▼ | $47.23M ▲ | $1.59M ▼ | $-54.67M ▲ |
| Q1-2025 | $-71.99M ▼ | $-66.51M ▼ | $69.38M ▲ | $24.97M ▲ | $27.84M ▲ | $-67.06M ▼ |
| Q4-2024 | $-67.93M ▲ | $-60.58M ▼ | $61.67M ▲ | $26K ▼ | $1.12M ▼ | $-60.65M ▼ |
| Q3-2024 | $-70.63M | $-51.98M | $60.19M | $624K | $8.83M | $-52.26M |
CEO
Andrew R. Robbins
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-11-09 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 129
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Guggenheim
Buy
Citigroup
Buy
Jefferies
Buy
Leerink Partners
Outperform
JP Morgan
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
FMR LLC
Shares:22.41M
Value:$846.81M
BLACKROCK, INC.
Shares:10.37M
Value:$391.86M
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Shares:9.05M
Value:$342.12M
Summary
Showing Top 3 of 218